Unmasking epithelial-mesenchymal transition in a breast cancer primary culture: A study report

BMC Research Notes

Volumn 5, Issue , 2012, Pages

  Minafra, Luigi ^a,b   Norata, Rossana ^b   Bravatà, Valentina ^a,b   Viola, Massimo ^c   Lupo, Carmelo ^d   Gelfi, Cecilia ^a,e   Messa, Cristina ^a,b,f,g  

^a CNR   (Italy)

^b Laboratorio di Tecnologie Oncologiche (LATO) HSR GGiglio   (Italy)

^c Unit of Internal Medicine   (Italy)

^d LA MADDALENA CANCER CENTER   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

^f UNIVERSITY OF MILANO BICOCCA   (Italy)

^g Nuclear Medicine Center   (Italy)

Author keywords

Breast cancer; Epithelial mesenchymal transition (EMT); Primary cell culture

Indexed keywords

ACTIN; CADHERIN; KERATIN; TUMOR MARKER; VIMENTIN;

ARTICLE; BREAST TUMOR; CELL LINE; CHEMISTRY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; PAGET NIPPLE DISEASE; PATHOLOGY; PHASE CONTRAST MICROSCOPY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMOOTH MUSCLE; TUMOR CELL CULTURE;

ACTINS; BREAST NEOPLASMS; CADHERINS; CARCINOMA, DUCTAL, BREAST; CELL LINE; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KERATINS; MICROSCOPY, PHASE-CONTRAST; MUSCLE, SMOOTH; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; VIMENTIN;

EID: 84863221222     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-5-343     Document Type: Article

References (34)

1. Gene-expression signatures in breast cancer. Sotiriou C, Pusztai L, N Engl J Med 2009 360 790 800 10.1056/NEJMra0801289 19228622
2. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Wang Y, Klijn JG, Zhang Y, et al. Lancet 2005 365 671 679 15721472
3. Genes associated with breast cancer metastatic to bone. Smid M, Wang Y, Klijn JG, et al. J Clin Oncol 2006 24 2261 2267 10.1200/JCO.2005.03.8802 16636340
4. Subtypes of breast cancer show preferential site of relapse. Smid M, Wang Y, Zhang Y, et al. Cancer Res 2008 68 3108 3114 10.1158/0008-5472.CAN-07-5644 18451135
5. Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. Rodriguez-Pinilla SM, Sarrio D, Honrado E, et al. Clin Cancer Res 2006 12 1533 1539 10.1158/1078-0432.CCR-05- 2281 16533778
6. Epithelial-Mesenchymal and Mesenchymal-Epithelial Transitions in Carcinoma Progression. Hugo H, Ackland ML, Blick T, et al. J Cell Physiol 2007 213 374 383 10.1002/jcp.21223 17680632
7. Transitions between epithelial and mesenchymal states in development and disease. Baum B, Settleman J, Quinlan MP, Semin Cell Dev Biol 2008 19 294 308 10.1016/j.semcdb.2008.02.001 18343170
8. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Yang J, Weinberg RA, Dev Cell 2008 14 818 829 10.1016/j.devcel.2008.05.009 18539112
9. Epithelial to mesenchymal transition and breast cancer. Tomaskovic-Crook E, Thompson EW, Thiery JP, Breast Cancer Res 2009 11 6 213 10.1186/bcr2416 19909494
10. A comparative study of cytokine gene transcripts in normal and malignant breast tissue and primary cell cultures derived from the same tissue samples. Speirs V, Green AR, White MC, Int J Cancer 1996 66 551 556 10.1002/(SICI)1097- 0215(19960516)66:4<551::AID-IJC21>3.0.CO;2-9 8635873
11. Transformation of MCF-10A cells by random mutagenesis with frameshift mutagen ICR191: A model for identifying candidate breast-tumor suppressors. Zientek-Targosz H, Kunnev D, Hawthorn L, et al. Mol Cancer 2008 7 51 10.1186/1476-4598-7-51 18534021
12. Human breast cancer cell lines co-express neuronal, epithelial, and melanocytic differentiation markers in vitro and in vivo. Zhang Q, Fan H, Shen J, Hoffman RM, Xing HR, PLoS One 2010 5 9712 10.1371/journal.pone.0009712 20300523
13. Signaling networks guiding epithelial-mesenchymal transitions during embryogenesis and cancer progression. Moustakas A, Heldin CH, Cancer Sci 2007 98 1512 1520 10.1111/j.1349-7006.2007.00550.x 17645776
14. Mechanisms of the epithelial-mesenchymal transition by TGF-beta. Wendt MK, Allington TM, Schiemann WP, Future Oncol 2009 5 1145 1168 10.2217/fon.09.90 19852727
15. Estrogen Regulates Snail and Slug in the Down-Regulation of E-Cadherin and Induces Metastatic Potential of Ovarian Cancer Cells through Estrogen Receptor. Park SH, Cheung LW, Wong AS, Leung PC, Mol Endocrinol 2008 22 2085 2098 10.1210/me.2007-0512 18550773
16. Transforming growth factor-β-induced epithelial-mesenchymal transition facilitates epidermal growth factor-dependent breast cancer progression. Wendt MK, Jason A, Smith BS, Schiemann WP, Oncogene 2010 29 6485 6498 10.1038/onc.2010.377 20802523
17. Actions of TGF-beta as tumor suppressor and pro-metastatic factor in human cancer. Pardali K, Moustakas A, Biochim Biophys Acta 2007 1775 21 62 16904831
18. Roles of TGFβ in metastasis. Padua D, Massagué J, Cell Res 2009 19 89 102 10.1038/cr.2008.316 19050696
19. TGF-β biology in breast: 15 years on. Barcellos-Hoff MH, J Mammary Gland Biol Neoplasia 2011 16 65 66 10.1007/s10911-011-9220-6 21534008
20. Autocrine production of TGF-beta confers resistance to apoptosis after an epithelial-mesenchymal transition process in hepatocytes: Role of EGF receptor ligands. Del Castillo G, Murillo MM, Alvarez-Barrientos A, et al. Exp Cell Res 2006 312 2860 2871 10.1016/j.yexcr.2006.05.017 16828470
21. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Peinado H, Olmeda D, Cano A, Nat Rev Cancer 2007 7 415 428 10.1038/nrc2131 17508028
22. Differential cadherin expression: potential markers for epithelial to mesenchymal transformation during tumor progression. Agiostratidou G, Hulit J, Phillips GR, Hazan RB, J Mammary Gland Biol Neoplasia 2007 2 127 133
23. Molecular mechanisms controlling E-cadherin expression in breast cancer. Baranwal S, Alahari SK, Biochem Biophys Res Commun 2009 384 6 11 10.1016/j.bbrc.2009.04.051 19379710
24. Integrins and cadherins join forces to form adhesive networks. Weber GF, Bjerke MA, De Simone DW, J Cell Sci 2011 124 1183 1193 10.1242/jcs.064618 21444749
25. Misregulated E-cadherin expression associated with an aggressive brain tumor phenotype. Lewis-Tuffin LJ, Rodriguez F, Giannini C, et al. PLoS One 2010 5 13665 10.1371/journal.pone.0013665 21060868
26. The cadherin switch in ovarian high-grade serous carcinoma is associated with disease progression. Quattrocchi L, Green AR, Martin S, Durrant L, Deen S, Virchows Arch 2011 459 21 29 10.1007/s00428-011-1082-1 21509572
27. N-cadherin expression is correlated with metastasis of spindle cell carcinoma of head and neck region. Nguyen PT, Kudo Y, Yoshida M, Iizuka S, Ogawa I, Takata T, J Oral Pathol Med 2011 40 77 82 10.1111/j.1600-0714.2010.00966.x 21070371
28. Changes in the expression of oestrogen receptors and E-cadherin as molecular markers of progression from normal epithelium to invasive cancer in elderly patients with vulvar squamous cell carcinoma. Zannoni GF, Prisco MG, Vellone VG, De Stefano I, Scambia G, Gallo D, Histopathology 2011 58 265 275 10.1111/j.1365-2559.2011.03744.x 21323952
29. P-cadherin expression in breast cancer: a review. Paredes J, Correia AL, Ribeiro AS, Albergaria A, Milanezi F, Schmitt FC, Breast Cancer Res 2007 9 1 12
30. N-cadherin signaling potentiates mammary tumor metastasis via enhanced extracellular signal-regulated kinase activation. Hulit J, Suyama K, Chung S, et al. Cancer Res 2007 67 3106 3116 10.1158/0008-5472.CAN-06-3401 17409417
31. Vimentin induces changes in cell shape, motility, and adhesion during the epithelial to mesenchymal transition. Mendez MG, Kojima S, Goldman RD, FASEB J 2010 24 1838 1851 10.1096/fj.09-151639 20097873
32. Novel functions of vimentin in cell adhesion, migration and signaling. Ivaska J, Pallari HM, Nevo J, Eriksson JE, Exp Cell Res 2007 313 2050 2062 10.1016/j.yexcr.2007.03.040 17512929
33. Down-regulation of vimentin expression inhibits carcinoma cell migration and adhesion. McInroy L, Määttä A, Biochem Biophys Res Commun 2007 360 109 114 10.1016/j.bbrc.2007.06.036 17585878
34. Vimentin is a novel anti-cancer therapeutic target; insights from in vitro and in vivo mice xenograft studies. Lahat G, Zhu QS, Huang KL, et al. PLoS One 2010 5 10105 10.1371/journal.pone.0010105 20419128